Dianthus | Affinity Screening

  • Dianthus: Tackle your most challenging affinity screenings with breakthrough Spectral Shift technology2:30

    Dianthus: Tackle your most challenging affinity screenings with breakthrough Spectral Shift technology

    Watch
  • Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift22:23

    Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift

    Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl

    Watch
  • How to keep your degrader pipeline moving forward with Dianthus16:42

    How to keep your degrader pipeline moving forward with Dianthus

    The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co

    Watch
  • Put your challenging affinity screening campaigns back on track — after you’ve tried everything else37:25

    Put your challenging affinity screening campaigns back on track — after you’ve tried everything else

    When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an

    Watch
  • Top 8 targeted protein degradation conferences of 2023 at a glance

    Top 8 targeted protein degradation conferences of 2023 at a glance

    Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.

    Read
  • Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Read
  • NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....

    Read
  • Ready to tackle your challenging affinity screening?

    Discover tools you can use

    Learn more
  • Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Read
  • Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus

    Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus

    Read
  • 10 terms to help you more easily understand targeted protein degradation

    10 terms to help you more easily understand targeted protein degradation

    Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...

    Read
  • Going small to win big: Fragment-based screening in drug discovery

    Going small to win big: Fragment-based screening in drug discovery

    Read
  • 9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...

    Read
  • Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Read
  • High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    Read
  • Why so many companies are betting on PROTACs as a superior therapeutic modality

    Why so many companies are betting on PROTACs as a superior therapeutic modality

    With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

    Read
  • Improve your protein degrader design with new ways to discover E3 ligase ligands35:47

    Improve your protein degrader design with new ways to discover E3 ligase ligands

    Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat

    Watch
  • MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development

    MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development

    Read
  • Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods

    Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods

    Read
  • Adventures in drug discovery - The quest for your best small molecule56:52

    Adventures in drug discovery - The quest for your best small molecule

    Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com

    Watch
  • How to improve the function of your PROTAC degrader by understanding ternary complex formation59:35

    How to improve the function of your PROTAC degrader by understanding ternary complex formation

    Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target

    Watch
  • loading
    Loading more...